Get started
Author

Marina Silvia Parisi

Observed names: M. S. PARISI, M. S. Parisi, M.S. parisi, MARINA PARISI, Marina Parisi, Marina S. Parisi, Parisi, Marina
Observed institutions: University of Catania, Policlinico Universitario di Catania, Centre Hospitalier Universitaire Ibn Rochd, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", The Medical City Ortigas, University of Hassan II Casablanca
ORCID: 0000-0002-6679-0856
Observed ORCID: 0000-0002-6679-0856
OpenAlex ID: A5104014232
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy
2018 · Alessandra Romano, Nunziatina Laura Parrinello, et al. · Expert Review of Molecular Diagnostics · 76
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
2017 · Alessandra Romano, Nunziatina Laura Parrinello, et al. · Blood Cancer Journal · 44
PDF
Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2024 · Sabina Chiaretti, Matteo Leoncin, et al. · Blood · 37
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
2021 · Serena Brancati, Lucia Gozzo, et al. · Cancers · 35
PDF
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
2019 · Concetta Conticello, Alessandra Romano, et al. · Journal of Clinical Medicine · 28
PDF
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
2021 · Lucia Gozzo, Calogero Vetro, et al. · Frontiers in Pharmacology · 24
PDF
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field
2022 · Andrea Duminuco, Cinzia Maugeri, et al. · Cancers · 23
PDF
Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions
2023 · Andrea Duminuco, Antonella Nardo, et al. · Cancer · 20
PDF
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
2019 · Marina Silvia Parisi, Salvatore Leotta, et al. · Journal of Clinical Medicine · 14
PDF
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data
2023 · Lucia Gozzo, Antonella Nardo, et al. · Healthcare · 13
PDF
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
2021 · Uros Markovic, Alessandra Romano, et al. · Frontiers in Oncology · 13
PDF
A case of high‐risk AML in a patient with advanced systemic mastocytosis
2023 · Manlio Fazio, Calogero Vetro, et al. · Clinical Case Reports · 10
PDF
Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment
2015 · Giuseppe Milone, Maria Grazia Camuglia, et al. · Experimental Hematology · 10
PDF
Pegylated Asparaginase‐Induced Liver Injury: A Case‐Based Review and Data From Pharmacovigilance
2022 · Calogero Vetro, Andrea Duminuco, et al. · The Journal of Clinical Pharmacology · 8
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases
2022 · Andrea Duminuco, Calogero Vetro, et al. · Hematology Reports · 8
PDF
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
2020 · Valeria Calafiore, Silvia Giamporcaro, et al. · Journal of Clinical Medicine · 8
PDF
Real-World Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort
2025 · Veronica Vecchio, Andrea Duminuco, et al. · Journal of Clinical Medicine · 6
PDF
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax
2025 · Fanny Palumbo, Andrea Duminuco, et al. · Journal of Clinical Medicine · 5
PDF
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
2023 · Andrea Duminuco, Uros Markovic, et al. · Frontiers in Immunology · 5
PDF
Pomalidomide Experience: An Effective Therapeutic Approach with Immunomodulatory Drugs in A Patient with Relapsed-Refractory Multiple Myeloma
2017 · Concetta Conticello, Marina Parisi, et al. · Future Oncology · 5
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
2022 · Alessandra Romano, Claudio Cerchione, et al. · Cancers · 4
PDF
Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine—Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement
2025 · Fanny E. Palumbo, Calogero Vetro, et al. · European Journal Of Haematology · 3
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study
2025 · Ermelinda Longo, Fanny Erika Palumbo, et al. · Journal of Clinical Medicine · 3
PDF
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study
2024 · Salvatore Leotta, Uros Markovic, et al. · Annals of Hematology · 3
PDF
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
2019 · Uros Markovic, Valeria Calafiore, et al. · Clinical Case Reports · 3
PDF
Works count: 51
Citation count: 422
H-index: 11
I10-index: 13
Year
Topic
Type